Richard I Steinhart insider trades
Open-market stock purchases and sales by Richard I Steinhart, Director at Actinium Pharmaceuticals, Inc, from SEC Form 4 filings since Mar 3, 2010.
Track record: 0% of 4 scored buys are up 5% or more since purchase, averaging -79%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc | Bought (not open market) | — |
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc | Bought (not open market) | — |
| Jun 15, 2026 | BTAI BioXcel Therapeutics, Inc | Bought (not open market) | — |
| May 20, 2026 | BTAI BioXcel Therapeutics, Inc | Sold | $7.4K |
| May 12, 2026 | ATOS Atossa Therapeutics, Inc | Bought (not open market) | — |
| May 4, 2026 | BTAI BioXcel Therapeutics, Inc | Bought (not open market) | — |
| May 1, 2026 | BTAI BioXcel Therapeutics, Inc | Bought (not open market) | — |
| Mar 15, 2026 | BTAI BioXcel Therapeutics, Inc | Bought (not open market) | — |
| Mar 14, 2026 | BTAI BioXcel Therapeutics, Inc | Bought (not open market) | — |
| Jan 1, 2026 | BTAI BioXcel Therapeutics, Inc | Bought (not open market) | — |
| Dec 15, 2025 | BTAI BioXcel Therapeutics, Inc | Bought (not open market) | — |
| Dec 14, 2025 | BTAI BioXcel Therapeutics, Inc | Bought (not open market) | — |
Companies traded
- ATNM Actinium Pharmaceuticals, Inc: 1 buy, last Sep 2, 2026
- BTAI BioXcel Therapeutics, Inc: 3 buys, 10 sales, last Jun 15, 2026
- ATOS Atossa Therapeutics, Inc: other filings, last May 12, 2026
- MELA Mela Sciences, Inc /NY: 2 buys, last Aug 5, 2013
- MHAN Manhattan Pharmaceuticals Inc: other filings, last Mar 3, 2010
Get free alerts when Richard I Steinhart files a new trade →